Product Code: GVR-4-68039-096-6
External Ventricular Drain Market Growth & Trends:
The global external ventricular drain market size is anticipated to reach USD 10.52 billion by 2030, expanding at a CAGR of 5.9% from 2023 to 2030, according to a new report by Grand View Research, Inc.. High incidence of hydrocephalus and subsequent increase in the number surgical procedure to treat this condition are driving the market. An external ventricular drain also known as ventriculostomy is a medical procedure performed to remove excess cerebrospinal fluid from the ventricles of the brain to maintain intracranial pressure. It is used for conditions such as severe head injury, hydrocephalus, intracranial hypertension, subarachnoid hemorrhages, and inflammatory diseases of the cerebrospinal space.
Rising prevalence of cerebrovascular disorders and traumatic brain injuries globally is leading to the increased demand for external ventricular drain, thereby propelling market growth. According to the Stroke Statistics 2018, over 100,000 people suffer from strokes in the U.K. every year. Out of which around 85.0% are ischemic strokes and 15.0% are haemorrhagic, which results in the blocking of blood flow to the brain.
Furthermore, incorporation of various modern technologies, and introduction of new products by market players, are likely to boost the market during the forecast period. For instance, in September 2017, Arkis BioSciences received U.S. FDA approval for its "CerebroFlo"- an external ventricular drainage catheter. It is used for insertion into ventricular cavity for external drainage of cerebrospinal fluid.
External Ventricular Drain Market Report Highlights:
- Based on application, the traumatic brain injury segment dominated the external ventricular drain market with a revenue share of 33.8% in 2022. This segment is also expected to expand at the fastest CAGR of 5.9% during the forecast period.
- North America dominated the market for external ventricular drain with a revenue share of 35.4% in 2022. This is owing to the greater incidence of traumatic brain injuries in the region, as well as a high prevalence of neurovascular disorders.
- In the Middle East and Africa, the market for external ventricular drain is expected to witness the fastest CAGR of 6.5% during the forecast period. This is due to the presence of a huge patient base in emerging regional economies, along with rising healthcare expenditures.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Application
- 1.1.2. Patient Type
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Patient Type outlook
- 2.2.2. Application outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. External Ventricular Drain Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.4. External Ventricular Drain Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's Five Forces
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic Landscape
Chapter 4. External Ventricular Drain Market: Application Estimates & Trend Analysis
- 4.1. External Ventricular Drain Market: Key Takeaways
- 4.2. External Ventricular Drain Market: Application Movement & Market Share Analysis, 2022 & 2030
- 4.3. Traumatic Brain Injury
- 4.3.1. Traumatic Brain Injury market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Subarachnoid Hemorrhage
- 4.4.1. Subarachnoid Hemorrhage market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Intracerebral Hemorrhage
- 4.5.1. Intracerebral Hemorrhage market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Other Non-traumatic Hydrocephalus Conditions
- 4.6.1. Other Non-traumatic Hydrocephalus Conditions market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. External Ventricular Drain Market: Patient Type Estimates & Trend Analysis
- 5.1. External Ventricular Drain Market: Key Takeaways
- 5.2. External Ventricular Drain Market: Patient Type Movement & Market Share Analysis, 2022 & 2030
- 5.3. Pediatric
- 5.3.1. Pediatric market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Adult
- 5.4.1. Adult market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. External Ventricular Drain Market: Regional Estimates & Trend Analysis
- 6.1. Regional Outlook
- 6.2. External Ventricular Drain Market by Region: Key Marketplace Takeaways
- 6.3. North America
- 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.3. Canada
- 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.2. Germany
- 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.3. France
- 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.4. Italy
- 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.5. Spain
- 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.6. Denmark
- 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.7. Sweden
- 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.8. Norway
- 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.2. China
- 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.3. India
- 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.4. Australia
- 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.5. Thailand
- 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.6. South Korea
- 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.2. Mexico
- 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7. MEA
- 6.7.1. South Africa
- 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.2. Saudi Arabia
- 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.3. UAE
- 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.2.1. Spiegelberg GmbH & Co. KG
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. Medtronic
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. Sophysa
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Neuromedex GmbH
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. Integra LifeSciences
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. Moller Medical GmbH
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. B. Braun SE
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. Fuji Systems
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives